Drug intelligence / Profile preview

PROT-002

Development stage: Preclinical
Lead developer: Protego Biopharma
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

PROT-002 is an investigational drug developed by Protego Biopharma, Inc. It is currently in preclinical development for the treatment of amyloidosis. While specific details on its mechanism of action are limited for PROT-002, related drugs from the same company are designed to bind to and stabilize misfolded proteins, preventing their toxic accumulation. This approach aims to impact disease progression rather than just symptoms.

Targets

AL (Amyloid light-chain protein)

Beyond the preview

Go deeper on PROT-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PROT-002.

Explore the full profile